Literature DB >> 9292008

A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera.

Z Wang1, N Christensen, J T Schiller, J Dillner.   

Abstract

A type-specific and neutralizing mouse MAb (V5) against human papillomavirus (HPV) type 16 capsids was found to block the serological reactivity of human sera with the corresponding capsids. Out of 352 human serum samples tested for the presence of IgG against HPV-16, more than 75% of reactive sera were completely blocked by the V5 antibody. Type-specific MAbs against HPV-6, -18 and -33 were also found to block serological reactivity with capsids of the corresponding HPV types for the majority of reactive human sera. The results suggest that most antibodies in human sera that are reactive with intact HPV capsids recognize the same or closely related major antigenic determinant(s).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292008     DOI: 10.1099/0022-1317-78-9-2209

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  35 in total

1.  Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells.

Authors:  Karina Araujo Aires; Aurora Marques Cianciarullo; Sylvia Mendes Carneiro; Luisa Lina Villa; Enrique Boccardo; Gaspar Pérez-Martinez; Isabel Perez-Arellano; Maria Leonor Sarno Oliveira; Paulo Lee Ho
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

2.  Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Authors:  Timothy D Culp; Christin M Spatz; Cynthia A Reed; Neil D Christensen
Journal:  Virology       Date:  2007-01-12       Impact factor: 3.616

3.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

Review 4.  The papillomavirus major capsid protein L1.

Authors:  Christopher B Buck; Patricia M Day; Benes L Trus
Journal:  Virology       Date:  2013-06-22       Impact factor: 3.616

5.  Development of a highly thermostable, adjuvanted human papillomavirus vaccine.

Authors:  Kimberly J Hassett; Natalie M Meinerz; Florian Semmelmann; Megan C Cousins; Robert L Garcea; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2015-05-18       Impact factor: 5.571

6.  Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization.

Authors:  Jian Guan; Stephanie M Bywaters; Sarah A Brendle; Hyunwook Lee; Robert E Ashley; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  Virology       Date:  2015-05-19       Impact factor: 3.616

7.  Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.

Authors:  Yevgeniy Y Studentsov; Gloria Y F Ho; Morgan A Marks; Robert Bierman; Robert D Burk
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy.

Authors:  Qinjian Zhao; Clinton S Potter; Bridget Carragher; Gabriel Lander; Jaime Sworen; Victoria Towne; Dicky Abraham; Paul Duncan; Michael W Washabaugh; Robert D Sitrin
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

9.  Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.

Authors:  Arvind Varsani; Anna-Lise Williamson; Debbie de Villiers; Inga Becker; Neil D Christensen; Edward P Rybicki
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.

Authors:  Andrea M Anonychuk; Chris T Bauch; Maraki Fikre Merid; Georges Van Kriekinge; Nadia Demarteau
Journal:  BMC Public Health       Date:  2009-10-31       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.